Skip to main content
SpringerLink
Log in

Elevated Alkaline Phosphatase Prior to Transarterial Chemoembolization for Neuroendocrine Tumors Predicts Worse Outcomes

  • Original Article
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Introduction

We hypothesized that an elevated preoperative alkaline phosphatase (AP) predicted worse outcomes for patients undergoing transarterial chemoembolization (TACE) for neuroendocrine tumor (NET) liver metastases.

Methods

We reviewed all patients who underwent TACE for metastatic NET between 2009 and 2013. Survival was evaluated using preprocedure variables.

Results

One hundred and nine patients underwent 210 TACE procedures. The average age was 57.7 years (range 20–78). Primary sites included pancreas (N = 20), other gastrointestinal (N = 52), lung (N = 9), and unknown (N = 28). The tumor was grade 1 in 68 (62 %), grade 2 in 21 (19 %), and grade 3 in 3 (3 %). Extrahepatic disease was present in 54 (50 %) and greater than 50 % hepatic tumor burden by imaging in 63 (58 %). Elevated bilirubin occurred in 8 (7 %), elevated AP in 22 (20 %), elevated ALT in 21 (19 %), and elevated AST in 41 (38 %). Univariate predictors included tumor grade (43 vs 27 vs 21 months, p = 0.015), hepatic tumor burden (59 vs 37 months, p = 0.009), and elevated AP (59 vs 23 months, p < 0.001). On multivariate analysis, only elevated AP (p = 0.001) predicted worse survival.

Conclusions

Elevated AP prior to TACE for metastatic NET portends a worse survival outcome, even more so than tumor grade or extent of hepatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kim SJ, Kim JW, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Seog Heo D, Bang YJ. Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy. BMC Cancer 2010;10:448

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  2. Mayo SK, Herman JM, Cosgrove D, Bhagat N, Kamel I, Geschwind JFH, Pawlik TM. Emerging approaches in the management of patients with neuroendocrine liver metastasis: Role of liver-directed and systemic therapies. J Am Coll Surg 2013;216(1):123–134

    Article  PubMed Central  PubMed  Google Scholar 

  3. Schmidt C, Bloomston M, Shah MH. Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies. Oncogene 2011;30:1497–1505

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  4. Burns WR, Edil BH. Neuroendocrine pancreatic tumors: Guidelines for management and update. Current Treatment Option in Oncology 2012;13:24–34

    Article  Google Scholar 

  5. Arrese D, McNally ME, Chokshi R, Feria-Arias E, Schmidt C, Klemanski D, Gregory G, Khabiri H, Shah M, Bloomston M. Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma. Ann Surg Oncol 2013;20:1114–1120

    Article  PubMed  Google Scholar 

  6. Vogl TJ, Naguib NNN, Zangos S, Eichler K, Hedayati A, Nour-Eldi NEA. Liver metastases of neuroendocrine carcinomas: Interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Euro J Rad 2009;72:517–528

    Article  Google Scholar 

  7. Ho AS, Picus J, Darcy MD, Tan B, Gould JE, Pilgram TK, Brown DB. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR 2007;188:1201–1207

    Article  PubMed  Google Scholar 

  8. Hoffmann RT, Paprottka P, Jakobs TF, Trumm CG, Reiser MG. Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization). Abdom Imaging 2011;36:671–676

    Article  PubMed  Google Scholar 

  9. Guiu B, Deschamps F, Aho S, Munck F, Dromain C, Boige V, Malka D, Leboulleux S, Ducreux M, Schlumberger M, Baudin E, de Baere T. Liver/biliary injuries following chemoembolization of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads. J Hepatology 2012;56:609–617

    Article  CAS  Google Scholar 

  10. Bhagat N, Reyes DK, Lin M, Kamel I, Pawlik TM, Frangakis C, Geshwind JF. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: High incidence of biliary injury. Cardiovasc Intervent Radiol 2013;36(2):449–459

    Article  PubMed Central  PubMed  Google Scholar 

  11. Whitney R, Valek V, Fages JF, Garcia A, Narayanan G, Tatum C, Hahl M, Martin RC 2nd. Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: A comparison of efficacy and cost. The Oncologist 2011;16:594–601

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  12. Akahori T, Sho M, Tanaka T, Nishiofuku H, Kinoshita S, Nagai M, Kichikawa K, Nakajima Y. Significant efficacy of new transcatheter arterial chemoembolization technique for hepatic metastases of pancreatic neuroendocrine tumors. Anticancer Research 2013;13:3355–3358

    Google Scholar 

  13. Glazer ES, Tseng JF, Al-Refaie W, Solorzano CC, Liu P, Willborn KA, Abdalla EK, Vauthey JN, Curley SA. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford) 2010;12:427–433

    Article  Google Scholar 

  14. Hur S, Chung JW, Kim HY, Oh DY, Lee SH, Bang YJ, Kim WH. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. J Vasc Interv Radiol 2013;24:947–956

    Article  PubMed  Google Scholar 

  15. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: Variables affecting response rates and survival. Cancer 2005;104(8):1590–1602

    Article  PubMed  Google Scholar 

  16. Varker KA, Martin EW, Klemanski D, Palmer B, Shah MH, Bloomston M. Repeat transarterial chemoembolization (TACE) for progressive hepatic carcinoid metastases provides results similar to first TACE. J Gastrointest Surg 2007;11(12):1680–5

    Article  PubMed  Google Scholar 

  17. Therasse P, ARbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verwij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205–16

    Article  PubMed  CAS  Google Scholar 

  18. Lewis MA, Jaramillo S, Roberts L, Fleming CJ, Rubin J, Grothey A. Hepatic artery embolization for neuroendocrine tumors: Postprocedural management and complications. The Oncologist 2012;17:725–731

    Article  PubMed Central  PubMed  Google Scholar 

  19. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA. Neuroendocrine hepatic metastases: Does aggressive management improve survival? Ann Surg 2005;241:776–785

    Article  PubMed Central  PubMed  Google Scholar 

  20. Reichling JJ, Kaplan MM. Clinical use of serum enzymes in liver disease. Dig Dis Sci 1988;33(12):1601–14

    Article  PubMed  CAS  Google Scholar 

  21. Bloomston M, Al-Saif O, Klemanski D, Pinzone JJ, Martin EW, Palmer B, Guy G, Khabiri H, Ellison EC, Shah MH. Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: Lessons learned. J Gastrointest Surg 2007;11:264–71

    Article  PubMed  Google Scholar 

  22. Janson ER, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, Oberg K. Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8(7):685–90.

    Article  PubMed  CAS  Google Scholar 

  23. Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH. Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig Dis Sci 2006;51(5):877–84.

    Article  PubMed  CAS  Google Scholar 

  24. Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, ARdill J, Johnston BT, Poston G, Rees M, Buxton-Thomas M, Caplin M, Ramage JK. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 2009;16(3):885–94.

    Article  PubMed  CAS  Google Scholar 

  25. Hur S, Chung JW, Kim HC, Oh DY, Lee SH, Bang YJ, Kim WH. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. J Vasc Interv Radiol 2013;24(7):947–56.

    Article  PubMed  Google Scholar 

  26. Dong XD, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol 2011;28:S286-S290

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, The Ohio State University Wexner Medical Center, 250 Cherry St, Grand Rapids, MI, 49503, USA

    Jill K. Onesti, Lawrence A. Shirley, Neil D. Saunders, Gail W. Davidson, Mary E. Dillhoff, Carl R Schmidt & Mark Bloomston

  2. Division of Interventional Radiology, The Ohio State University Wexner Medical Center, 250 Cherry St, Grand Rapids, MI, 49503, USA

    Hooman Khabiri, Gregory E. Guy & Joshua D. Dowell

  3. Division of Medical Oncology, The Ohio State University Wexner Medical Center, 250 Cherry St, Grand Rapids, MI, 49503, USA

    Manisha H. Shah

Authors
  1. Jill K. Onesti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lawrence A. Shirley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neil D. Saunders
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gail W. Davidson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mary E. Dillhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hooman Khabiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gregory E. Guy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Joshua D. Dowell
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Carl R Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Manisha H. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mark Bloomston
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jill K. Onesti.

Ethics declarations

Disclosures

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Onesti, J.K., Shirley, L.A., Saunders, N.D. et al. Elevated Alkaline Phosphatase Prior to Transarterial Chemoembolization for Neuroendocrine Tumors Predicts Worse Outcomes. J Gastrointest Surg 20, 580–586 (2016). https://doi.org/10.1007/s11605-015-2998-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-015-2998-6

Keywords

Search

Navigation